Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 609
- Registration Number
- NCT02174861
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom
Darbepoetin Alfa MDS Companion Protocol
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 9
- Registration Number
- NCT02175277
- Locations
- 🇧🇪
Research Site, Sint-Niklaas, Belgium
Registry Study for Talimogene Laherparepvec
Completed
- Conditions
- Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
- Interventions
- Other: Information collection
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 185
- Registration Number
- NCT02173171
- Locations
- 🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps
Phase 1
Completed
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT02170337
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
Phase 3
Completed
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 394
- Registration Number
- NCT02157948
- Locations
- 🇵🇱
Research Site, Warszawa, Poland
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
- Conditions
- Unresected Stage IIIb to IVM1c Melanoma
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Amgen
- Registration Number
- NCT02147951
- Locations
- 🇺🇸
Research Site, Wauwatosa, Wisconsin, United States
Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis
Phase 3
Terminated
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism
- Interventions
- Dietary Supplement: Standard of Care
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 55
- Registration Number
- NCT02138838
- Locations
- 🇺🇦
Research Site, Kyiv, Ukraine
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
Phase 3
Terminated
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 34
- Registration Number
- NCT02137343
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 16
- Registration Number
- NCT02132429
- Locations
- 🇺🇸
CRI Lifetree, Salt Lake City, Utah, United States
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Biological: ABP 501
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 467
- Registration Number
- NCT02114931
- Locations
- 🇬🇧
Research Site, Suffolk, England, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath